Effects of Prescription Omega-3-Acid Ethyl Esters on Fasting Lipid Profile in Subjects With Primary Hypercholesterolemia

• DOI: 10.1097/fjc.0b013e318210fca5
• Publication Date: 2011-02-05T07:07:53Z
• Authors: Kevin C Maki; Andrea L Lawless; Kathleen M Kelley; Mary R Dicklin; Valerie N Kaden; Arianne L Schild; Tia M Rains; John W Marshall
• Keywords: Dyslipidemia; Lipoprotein particle; Crossover study; High-density lipoprotein; Low-density lipoprotein; Lipid Profile

This double-blind, randomized crossover study investigated the effects of 6 weeks treatment with prescription omega-3-acid ethyl esters (POM3, 4 g/day) versus placebo (soy oil) on low-density lipoprotein cholesterol (LDL-C) and other aspects fasting lipid profile in 31 men women primary, isolated hypercholesterolemia (LDL-C 130-220 mg/dL triglycerides less than 150 while free lipid-altering therapies). Mean ± standard error mean baseline concentrations total cholesterol, LDL-C, high-density (HDL-C), very-low-density were 229 3, 146 60 2, 23 113 8 mg/dL, respectively. POM3 produced a modest increase from LDL-C (3.4%) response (-0.7%, P = 0.010). Significant changes (P < 0.05) for (placebo-corrected) observed (-18.8%), (-18.7%), HDL-C (3.3%). Nuclear magnetic resonance-determined particle concentration size HDL decreased significantly more placebo, whereas LDL sizes increased placebo. Total non-HDL-C, apolipoproteins A1 B, responses did not differ between treatments. These results confirm hypothesis that would lower hypercholesterolemia. Effects variables consistent prior mixed dyslipidemia.